Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Stearyl Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.69 |
| ▸ | ATM | Q13315 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | PRKCA | P17252 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL19210220 | 1.00 | HCAR2 (0.69) | HCAR2ATMMAPTRAB9ANPSR1 | |
| Potassium Ion SCHEMBL11798286 | 1.00 | HCAR2 (0.69) | HCAR2ATMMAPTRAB9ANPSR1 | |
| Potassium Ion SCHEMBL11803005 | 1.00 | HCAR2 (0.69) | HCAR2ATMMAPTRAB9ANPSR1 | |
| Stearyl Fumaric Acid SCHEMBL2431953 | 1.00 | HCAR2 (0.69) | HCAR2ATMMAPTRAB9ANPSR1 | |
| Potassium Ion SCHEMBL11798639 | 1.00 | HCAR2 (0.69) | HCAR2ATMMAPTRAB9ANPSR1 | |
| Potassium Ion SCHEMBL11798301 | 1.00 | HCAR2 (0.69) | HCAR2ATMMAPTRAB9ANPSR1 | |
| Potassium Ion SCHEMBL11798647 | 1.00 | HCAR2 (0.69) | HCAR2ATMMAPTRAB9ANPSR1 | |
| Potassium Ion SCHEMBL11801795 | 1.00 | HCAR2 (0.69) | HCAR2ATMMAPTRAB9ANPSR1 | |
| Stearyl Fumaric Acid SCHEMBL25396 | 0.96 | HCAR2 (0.69) | HCAR2ATMMAPTRAB9ANPSR1 | |
| SCHEMBL9679071 | 0.96 | HCAR2 (0.69) | HCAR2ATMMAPTRAB9ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719357-A1 | COMPOSITIONS COMPRISING SOTORASIB | Amgen Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| WO-2024249660-A1 | COMPOSITIONS COMPRISING SOTORASIB | AMGEN INC. (US) | 2024-12-05 | — | — | WO | claimed |
| US-20240226020-A1 | SOTORASIB FORMULATION | AMGEN INC. | 2024-07-11 | — | — | US | claimed |
| EP-4333813-A1 | SOTORASIB FORMULATION | AMGEN INC. (US) | 2024-03-13 | — | — | EP | claimed |
| CN-117222403-A | Soto-raschib formulation | 安进公司 | 2023-12-12 | — | — | CN | claimed |
| CN-116649523-A | Quinoa effervescent tablet and preparation method thereof | 内蒙古科技大学 | 2023-08-29 | — | — | CN | claimed |
| WO-2022235904-A1 | SOTORASIB FORMULATION | AMGEN INC. (US) | 2022-11-10 | — | — | WO | claimed |
| US-10945960-B2 | Celecoxib and amlodipine formulation and method of making the same | DEXCEL LTD. (IL) | 2021-03-16 | — | — | US | claimed |
| US-10925835-B2 | Celecoxib and amlodipine formulation and method of making the same | DEXCEL LTD. (IL) | 2021-02-23 | — | — | US | claimed |
| US-20200390713-A1 | CELECOXIB AND AMLODIPINE FORMULATION AND METHOD OF MAKING THE SAME | PURPLE BIOTECH LTD (IL) | 2020-12-17 | — | — | US | claimed |
| CN-111065382-A | Formula of celecoxib and amlodipine and preparation method thereof | 德西尔公司 | 2020-04-24 | — | — | CN | claimed |
| US-20190282507-A1 | CELECOXIB AND AMLODIPINE FORMULATION AND METHOD OF MAKING THE SAME | PURPLE BIOTECH LTD (IL) | 2019-09-19 | — | — | US | claimed |
| US-20190125792-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING FERRIC CITRATE AND METHODS FOR THE PRODUCTION THEREOF | DEXCEL PHARMA TECHNOLOGIES LTD. (IL) | 2019-05-02 | — | — | US | claimed |
| WO-2019008583-A1 | CELECOXIB AND AMLODIPINE FORMULATION AND METHOD OF MAKING THE SAME | DEXCEL LTD. (IL) | 2019-01-10 | — | — | WO | claimed |
| US-20190008777-A1 | CELECOXIB AND AMLODIPINE FORMULATION AND METHOD OF MAKING THE SAME | PURPLE BIOTECH LTD (IL) | 2019-01-10 | — | — | US | claimed |
| CN-107753507-A | Multivitamin and mineral substance composite effervescent tablet and preparation method thereof | 宜兴市江山生物科技有限公司 | 2018-03-06 | — | — | CN | claimed |
| EP-4719357-A1 | COMPOSITIONS COMPRISING SOTORASIB | Amgen Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024249660-A1 | COMPOSITIONS COMPRISING SOTORASIB | AMGEN INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-5254349-A | Flocculating drug and hydrophilic polymer in dosage form | ALZA CORPORATION (US) | 1993-10-19 | — | — | US | disclosed |
| US-5200195-A | Reducing stickiness of a dosage for to biological tissue in fluid environment of use | ALZA CORPORATION (US) | 1993-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226020-A1 | SOTORASIB FORMULATION | BAK1, S1PR5, DSG1 | HCAR2 2621/4885ATM 809/4885MAPT 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.